Olaussen KA - Search Results

1

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.

Facchinetti F, Loriot Y, Brayé F, Vasseur D, Bahleda R, Bigot L, Barbé R, Nobre C, Combarel D, Michiels S, Italiano A, Smolenschi C, Tselikas L, Scoazec JY, Ponce-Aix S, Besse B, André F, Olaussen KA, Hollebecque A, Friboulet L. Facchinetti F, et al. Among authors: olaussen ka. Clin Cancer Res. 2024 Nov 1;30(21):4943-4956. doi: 10.1158/1078-0432.CCR-24-1834. Clin Cancer Res. 2024. PMID: 39226398 Free PMC article.

2

Telomeres and telomerase as targets for anticancer drug development.

Olaussen KA, Dubrana K, Domont J, Spano JP, Sabatier L, Soria JC. Olaussen KA, et al. Crit Rev Oncol Hematol. 2006 Mar;57(3):191-214. doi: 10.1016/j.critrevonc.2005.08.007. Crit Rev Oncol Hematol. 2006. PMID: 16469501 Review.

3

ERCC1-specific immunostaining in non-small-cell lung cancer.

Olaussen KA, Fouret P, Kroemer G. Olaussen KA, et al. N Engl J Med. 2007 Oct 11;357(15):1559-61. doi: 10.1056/NEJMc072007. N Engl J Med. 2007. PMID: 17928611 No abstract available.

4

Telomere length, telomeric proteins and genomic instability during the multistep carcinogenic process.

Raynaud CM, Sabatier L, Philipot O, Olaussen KA, Soria JC. Raynaud CM, et al. Among authors: olaussen ka. Crit Rev Oncol Hematol. 2008 May;66(2):99-117. doi: 10.1016/j.critrevonc.2007.11.006. Epub 2008 Feb 14. Crit Rev Oncol Hematol. 2008. PMID: 18243729 Review.

5

Are RAS mutations predictive markers of resistance to standard chemotherapy?

Loriot Y, Mordant P, Deutsch E, Olaussen KA, Soria JC. Loriot Y, et al. Among authors: olaussen ka. Nat Rev Clin Oncol. 2009 Sep;6(9):528-34. doi: 10.1038/nrclinonc.2009.106. Epub 2009 Jul 14. Nat Rev Clin Oncol. 2009. PMID: 19597509 Review.

6

ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy.

Besse B, Massard C, Haddad V, Andre F, Dunant A, Pirker R, Olaussen KA, Brambilla E, Fouret P, Soria JC. Besse B, et al. Among authors: olaussen ka. Ann Oncol. 2011 Mar;22(3):575-581. doi: 10.1093/annonc/mdq407. Epub 2010 Aug 26. Ann Oncol. 2011. PMID: 20801905 Free article.

7

Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC.

Friboulet L, Barrios-Gonzales D, Commo F, Olaussen KA, Vagner S, Adam J, Goubar A, Dorvault N, Lazar V, Job B, Besse B, Validire P, Girard P, Lacroix L, Hasmats J, Dufour F, André F, Soria JC. Friboulet L, et al. Among authors: olaussen ka. Clin Cancer Res. 2011 Sep 1;17(17):5562-72. doi: 10.1158/1078-0432.CCR-11-0790. Epub 2011 Jul 12. Clin Cancer Res. 2011. PMID: 21750204

8

DNA repair capacity in circulating lymphocytes and influence on platinum effect in tumor cells.

Olaussen KA, André F, Soria JC. Olaussen KA, et al. J Clin Oncol. 2012 May 1;30(13):1567-8; author reply 1568-9. doi: 10.1200/JCO.2011.40.9888. Epub 2012 Mar 19. J Clin Oncol. 2012. PMID: 22430265 No abstract available.

9

Prognostic value of LIPC in non-small cell lung carcinoma.

Galluzzi L, Goubar A, Olaussen KA, Vitale I, Senovilla L, Michels J, Robin A, Dorvault N, Besse B, Validire P, Fouret P, Behrens C, Wistuba II, Soria JC, Kroemer G. Galluzzi L, et al. Among authors: olaussen ka. Cell Cycle. 2013 Feb 15;12(4):647-54. doi: 10.4161/cc.23517. Epub 2013 Jan 23. Cell Cycle. 2013. PMID: 23343765 Free PMC article.

10

ERCC1 and RRM1: ready for prime time?

Besse B, Olaussen KA, Soria JC. Besse B, et al. Among authors: olaussen ka. J Clin Oncol. 2013 Mar 10;31(8):1050-60. doi: 10.1200/JCO.2012.43.0900. Epub 2013 Feb 11. J Clin Oncol. 2013. PMID: 23401439 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters